Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CEP78 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | PROSER1 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | RAB22A | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-06 |
mRNA | NBPF10 | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-06 |
mRNA | SMAD9 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
mRNA | DCHS1 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
mRNA | SHC2 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | HTATIP2 | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-06 |
mRNA | RIC8B | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
mRNA | ZDHHC17 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |